Artificial intelligence (AI), machine learning (ML), and deep learning (DL) are gaining increased interest in many fields, into pharmaceutical Research has catalyzed transformative advancements across drug discovery, clinical development, manufacturing, and postmarket surveillance. This review comprehensively examines AI's role in modern pharmacotherapy, beginning with its historical evolution in life sciences and progressing to cutting-edge applications such as AlphaFolddriven protein modeling, natural language processing (NLP) for biomedical literature mining, and AIaugmented pharmacovigilance. Methodologically, we synthesize interdisciplinary insights from peer-reviewed literature (2013–2026), highlighting innovations in cheminformatics (e.g., QSAR, RDKit), predictive toxicology, and personalized medicine. Case studies illustrate AI's capacity to compress drug development timelines, as seen in COVID-19 repurposing efforts and de novo kinase inhibitor design. However, challenges persist, including algorithmic bias, regulatory ambiguities, and the “black-box” nature of deep learning models. By critically evaluating successes and limitations, this review underscores AI's potential to redefine pharmaceutical innovation while advocating for robust frameworks to ensure ethical, transparent, and clinically translatable AI deployment
Adarsh Pratap Singh1, Sandeep Prakash*1, Saurabh Kumar1, Neha Gautam1, Firdous Bano1, Harshit Gupta1, Lavkush Maurya1, Sandeep Kumar1, Sneh Lata1, Ajay Kmar1 (Mon,) studied this question.